Healthcare [ 4/11 ] | Biotechnology [ 53/112 ]
SG | NASDAQ | Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Apr 28, 23 | -1.29 Decreased by -35.79% | -4.05 Increased by +16.83% |
| Mar 24, 23 | -1.04 Decreased by -30.00% | -0.89 Decreased by -18.94% |
| Oct 28, 22 | -0.80 Decreased by -33.33% | -0.95 Increased by +16.62% |
| Aug 12, 22 | -0.95 Decreased by -171.43% | -0.60 Decreased by -97.22% |
| Apr 27, 22 | -0.95 Decreased by -46.15% | -0.52 Decreased by -159.02% |
| Mar 25, 22 | -0.80 Increased by +78.67% | -0.72 Decreased by -15.43% |
| Oct 26, 21 | -0.60 Decreased by -20.00% | -0.65 Increased by +11.83% |
| Aug 6, 21 | -0.35 Increased by +86.00% | -0.55 Increased by +66.12% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 23 | 0.00 Decreased by N/A% | -19.11 M Decreased by -48.19% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -14.48 M Decreased by -69.28% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -10.93 M Decreased by -101.32% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by N/A% | -12.89 M Decreased by -295.32% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0.00 Decreased by N/A% | -12.90 M Decreased by -225.75% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 21 | 0.00 Decreased by N/A% | -8.55 M Decreased by -64.98% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 21 | 0.00 Decreased by N/A% | -5.43 M Increased by +31.55% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 20 | 0.00 Decreased by N/A% | -3.26 M Increased by +70.94% | Decreased by N/A% Decreased by N/A% |
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.